QUOTE AND NEWS
Benzinga  Mar 17  Comment 
Novogen Limited (NASDAQ: NVGN) today announced that it has received a cash refund of $2.8M from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2015. This will support the Company's...
The Australian  Mar 13  Comment 
Drug company Novogen has backed away from increasing directors’ pay by almost two-thirds after an investor backlash.
Benzinga  Feb 19  Comment 
Novogen Limited (NASDAQ: NVGN) today announced that a patent for the superbenzopyran (SBP) family, covering the lead candidates Cantrixil and Trilexium, has been granted in Australia. This patent provides full protection of Novogen's intellectual...
Benzinga  Feb 5  Comment 
Novogen Limited (NASDAQ: NVGN), announced today the appointment of a new Chairman, Mr John O'Connor, and new Deputy Chairman, Mr Bryce Carmine, effective immediately. Incoming CEO, Dr James Garner, has also been formally appointed to the...
The Australian  Dec 9  Comment 
Drug research company appoints Dr James Garner to the role of CEO, taking over from interim chief Iain Ross.
Benzinga  Nov 24  Comment 
Novogen Limited (NASDAQ: NVGN), announced today that it has engaged Novotech as the Contract Research Organisation (CRO) to conduct its Phase 1 clinical study for the drug candidate, Cantrixil, which will commence in 2016. This first-in-human...
Benzinga  Nov 16  Comment 
Novogen Limited (NASDAQ: NVGN) today announced that it had signed an Underwriting Agreement with Lodge Partners to underwrite the outstanding options exercisable at $0.125 per option, which expire on 18 November 2015. The exercise of options...
Benzinga  Nov 12  Comment 
Novogen Limited (NASDAQ: NVGN) today announced that a patent application covering two of its key lead superbenzopyran (SBP) drug candidates has been accepted in Australia.  According to Novogen North America CEO, Dr Andrew Heaton, this patent...
Benzinga  Nov 10  Comment 
US-Australian drug discovery company, Novogen Limited (NASDAQ: NVGN), today announced details of preclinical studies which confirm the efficacy of the lead anti-tropomyosin (ATM) compound, Anisina, when delivered using a clinically relevant...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki